Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

--Data from Ongoing Glioblastoma Dosimetry Trial Accepted for Oral Presentation at 2009 Society of Nuclear Medicine Annual Meeting --

--Over 65 Recurrent GBM Patients in Phase I and Phase II Clinical Trials Have Received Cotara to Date, with a Good Safety Profile and Longer-Term Survivors Seen in All Studies--

TUSTIN, Calif., May 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today provided an update on progress in the company's clinical program for Cotara(R), a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that patient enrollment in the final cohort of a second Cotara GBM trial, a dose confirmation and dosimetry study, is nearing completion and that interim data from this trial has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009.

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from time of disease recurrence.

In the ongoing Phase II safety and efficacy trial, over half of the 40 planned GBM patients have been dosed with Cotara and patient follow-up is continuing. Screening for the anticipated final patient in the dose confirmation and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... opioid overdose deaths was outlined yesterday in the ... agencies in the U.S. Department of Health and Human ... to expand their use of medications to treat opioid ... of misperceptions that have limited access to these potentially ... be used in combination with behavior therapies to help ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... in laser skin treatments combines two radio frequency modes into one device. ... tighten skin by focusing laser on both shallow and deep tissue depths. ... by New York,s Juva Skin and Laser Center. , ... New York, ...
... treatment for ... Germany,s 300,000 physicians, ISMANING, Germany, Nov. ... SMY), a leading provider of solutions,that open the Digital World, ... program: the eHealth500 mobile terminal., The eHealth500 mobile terminal ...
... York, NY, November 13, 2008Compared to patients in seven ... are far more likely to forgo care because of ... errors, coordination problems, and high out-of-pocket costs, according to ... as a Web Exclusive in the journal Health ...
... from thousands of members, SEIU officials shut down,California ... 12 Caregivers who work in,California hospitals, nursing ... and Oakland offices of their national union, the ... members of United Healthcare Workers-West (UHW), a,local union ...
... following is a,statement by Larry Minnix, President & CEO, ... "We applaud Senator Baucus for releasing a health care ... alignment with our Five Big,Ideas to transform aging services. ... and technology in its efforts to,determine how our health ...
... Operating Former Conseco Senior,Health Insurance Company Long-Term ... Policyholders, HARRISBURG, Pa., Nov. 12 ... that it has approved the,separation, effective today, ... Conseco Senior Health Insurance Company) ("SHIP"),from Conseco, ...
Cached Medicine News:Health News:Accent Dual Mode Skin Tightening Laser is Latest Offering from Juva Skin Center 2Health News:SCM Microsystems Introduces New Mobile Terminal for the German Electronic Health Card 2Health News:SCM Microsystems Introduces New Mobile Terminal for the German Electronic Health Card 3Health News:New survey: More than half of US chronically ill adults skip needed care due to costs 2Health News:New survey: More than half of US chronically ill adults skip needed care due to costs 3Health News:New survey: More than half of US chronically ill adults skip needed care due to costs 4Health News:New survey: More than half of US chronically ill adults skip needed care due to costs 5Health News:Healthcare Workers Picket Their National Union to Protect Their Voice for Patients 2Health News:Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging on the Release of Sen. Baucus's Health Care Reform Proposal 2Health News:Pennsylvania Insurance Department Approves Launch of Senior Health Care Oversight Trust 2
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Sept. 29, 2011 A west coast secret is finally ... the way from Beverly Hills, California, a health and beauty ... ( www.endlessyouthandlife.com ).  A clinically tested dietary supplement is helping ... in less than 4 weeks of use.  Just a few ...
... Sept. 29, 2011 Terumo Americas Holdings, Inc., a ... anniversary of Terumo Corporation,s founding in 1921.  Terumo Corporation ... with $4 billion in annual sales and operations in ... Forbes magazine ranked Terumo Corporation 14th of the ...
Cached Medicine Technology:Beverly Hills Secret Now Helping People Across The Country 2Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary 2Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary 3
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
Medicine Products: